Navigation Links
New Clinical Study Finds that Nutraceutical Deepak Chopra Endorphinate® Provides Effective, Safe Relief for Chronic Anxiety, Depression, Cravings & Pain Hypersensitivity

Carlsbad, California (PRWEB) September 27, 2013

Groundbreaking research published this week in the Journal of Behavioral and Brain Science* (JBBS) shows that the nutraceutical Endorphinate® is a clinically effective and safe treatment for chronic emotional and physical distress, including anxiety, anger, depression, cravings, and pain hypersensitivity.

Developed by a team of scientists associated with mind-body healing pioneer and endocrinologist Deepak Chopra, M.D., and world-renowned neurologist and Alzheimer’s researcher Dr. Rudolph Tanzi, Endorphinate is a scientific formulation of health-promoting plant extracts and amino acids that is produced and distributed worldwide by Pondera Pharmaceuticals, Inc. Endorphinate® has a direct effect on endorphins, which are natural brain chemicals that create a sense of calm, pleasure, and wellbeing. Endorphinate® combines specific agents that increase the release of endorphins with agents that switch endorphin receptors from an excitatory (distress/pain) to an inhibitory (calm/comfort) mode.

As the peer-reviewed study published in JBBS describes, a team of scientists led by Dr. Stanley M. Crain, Professor Emeritus, Dept. of Neuroscience, Albert Einstein College of Medicine, and Dr. Steven Crain, neuropsychotherapist carried out a 26-month study to assess the benefits of Endorphinate® for individuals suffering from moderate-to-severe emotional and/or physical distress. Through direct treatment and close clinical supervision by Dr. Steven Crain, researchers conducted 203 clinical case studies of both females and males ranging in age from 14 to 85.

The study found that Endorphinate® provided strong clinical benefits, including reduced anxiety, anger, depressed mood, pain hypersensitivity, and cravings. Most participants reported greater calm, comfort, well-being, and pleasure as well as increased mental clarity, energy, productivity, healthier lifestyle choices, and an adaptive response to life’s stresses.

“It’s wonderful to have scientific data supporting the benefits of a natural, non-prescription supplement like Endorphinate®,” said Deepak Chopra. “I have been taking Endorphinate® every day for over a year and have been experiencing its beneficial effects. It has become the number one dietary supplement used by our clients and patients at the Chopra Center. I unhesitatingly endorse and support the use of Endorphinate® to help increase resistance to stress, anxiety, trauma, cravings, and fatigue."

*Steven Crain, Matthew A. Crain, and Stanley M. Crain, “Emotional and Physical
Distress Relief Using a Novel Endorphinergic Formulation,” Journal of Behavioral and Brain Science, Vol. 3, Issue 6, 2013, pp. 441-453. (Link to Article)

For press inquiries and interviews about the science of endorphins and the new study of Endorphinate published in the Journal of Behavioral and Brain Science, contact:

Steven Crain, Ph.D.
Neuropsychotherapist, Therapeutic Alliance
Clinical Director, Pondera Pharmaceuticals Inc.
315 S. Allen St., Suite 422
State College, PA 16801

For press inquiries about Deepak Chopra and the Chopra Center for Wellbeing, please contact:

Kathy Bankerd
Chopra Center Marketing Director
(760) 494-1609

About Deepak Chopra, M.D., F.A.C.P.
Founder of the Chopra Center for Wellbeing
Deepak Chopra, M.D. is the author of more than 65 books, including numerous New York Times bestsellers. His medical training is in internal medicine and endocrinology, and he is a Fellow of the American College of Physicians, a member of the American Association of Clinical Endocrinologists, and an adjunct professor of Executive Programs at the Kellogg School of Management at Northwestern University. He is also a Distinguished Executive Scholar at Columbia Business School, Columbia University, and a Senior Scientist at the Gallup organization. For more than a decade, he has participated as a lecturer at the Update in Internal Medicine, an annual event sponsored by Harvard Medical School’s Department of Continuing Education and the Department of Medicine, Beth Israel Deaconess Medical Center.


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: